Tom Williams/Vaccine

Coverage and timeliness of vaccination and the validity of routine estimates: Insights from a vaccine registry in Kenya.Adetifa, I. M. O. Karia, B. Mutuku, A. Bwanaali, T. Makumi, A. Wafula, J. Chome, M. Mwatsuma, P. Bauni, E. Hammitt, L. L. Mataza, C. Tabu, C. Kamau, T. Williams, T. N. Scott, J. A. G.
Vaccine, (2018). 36:7965-7974

High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.Polley, S. D. Conway, D. J. Cavanagh, D. R. McBride, J. S. Lowe, B. S. Williams, T. N. Mwangi, T. W. Marsh, K.
Vaccine, (2006). 24:4233-46

Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria.Polley, S. D. Mwangi, T. Kocken, C. H. Thomas, A. W. Dutta, S. Lanar, D. E. Remarque, E. Ross, A. Williams, T. N. Mwambingu, G. Lowe, B. Conway, D. J. Marsh, K.
Vaccine, (2004). 23:718-28